NLRP3 and atherosclerosis: Thus, perhaps the discovery of clinically approved novel pharmacological molecular inhibitors of NLRP3, along with other adjuvant therapy agents, may bring new therapeutic strategies with a reduced burden of atherosclerosis complications.